# US 2004/0072188 A1 · Novel receptor nucleic acids and polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072188 A1
- Document ID: US20040072188A1
- Status: Published application
- Kind: A1
- Application number: 10/380,703
- Filed: 2003-07-28
- Published: 2004-04-15
- Earliest claimed: 2003-07-28
- Assignees: Biogen Idec MA Inc.
- Inventors: Christine M. Ambrose; Jeffrey S. Thompson
- Web page: https://patentgrep.com/patent/US20040072188A1

## CPC

- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

## Claims

### Claim 1

An isolated nucleic acid comprising a sequence encoding a polypeptide at least 50% identical to a polypeptide comprising the amino acid sequence of SEQ ID NO:5.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein said nucleic acid encodes a polypeptide at least 90% identical to SEQ ID NO:5.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein said encoded polypeptide binds BAFF.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein said nucleic acid is DNA.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein said nucleic acid is RNA.

### Claim 6 (depends on 1)

The nucleic acid of claim 1, wherein said nucleic acid is a cDNA molecule.

### Claim 7

An isolated nucleic acid comprising a nucleotide sequence complementary to at least a portion of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6.

### Claim 8 (depends on 1, 2)

A vector comprising the nucleic acid of claims 1 or 2.

### Claim 9 (depends on 8)

A cell comprising the vector of claim 8.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1, 2)

A substantially purified polypeptide encoded by the nucleic acid of claims 1 or 2.

### Claim 12 (depends on 11)

A pharmaceutical composition comprising the polypeptide of claim 11 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

An antibody which binds specifically to the polypeptide of claim 12.

### Claim 14 (depends on 12)

An antibody that binds to an epitope on a polypeptide of claim 12.

### Claim 15 (depends on 12)

A kit comprising an antibody that binds to a polypeptide of claim 12, and, optionally, a negative control antibody.

### Claim 16 (depends on 13)

A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 9)

A method of producing a BAFF-R polypeptide, the method comprising:
providing the cell of claim 9;
culturing said cell under conditions sufficient to express said BAFF-R polypeptide; and
recovering said BAFF-R polypeptide, thereby producing said BAFF-R polypeptide.

### Claim 18 (depends on 17)

The method of claim 17, wherein said cell is a prokaryotic cell.

### Claim 19 (depends on 17)

The method of claim 17, wherein said cell is a eukaryotic cell.

### Claim 20

A method of diagnosing a B-cell mediated condition in a subject, the method comprising:
providing a protein sample from said subject;
measuring the amount of BAFF-R polypeptide in said subject sample; and
comparing the amount of BAFF-R polypeptide in said subject protein sample to the amount of BAFF-R polypeptide in a control protein sample, wherein an alteration in the amount of BAFF-R polypeptide in said subject protein sample relative to the amount of BAFF-R polypeptide in said control protein sample indicates the subject has a B-cell mediated condition.

### Claim 21 (depends on 20)

The method of claim 20, wherein said B-cell mediated condition is an autoimmune disorder.

### Claim 22 (depends on 20)

The method of claim 20, wherein said B-cell mediated condition is cancer.

### Claim 23

A method of diagnosing a B-cell mediated condition in a subject, the method comprising:
providing a nucleic acid sample from said subject;
measuring the amount of BAFF-R nucleic acid in said subject nucleic acid sample; and
comparing the amount of BAFF-R nucleic acid sample in said subject nucleic acid to the amount of BAFF-R nucleic acid in a control sample, wherein an alteration in the amount of BAFF-R nucleic acid in said sample relative to the amount of BAFF-R in said control sample indicates the subject has a B-cell mediated condition.

### Claim 24 (depends on 23)

The method of claim 23, wherein the measured BAFF-R nucleic acid is BAFF-R RNA.

### Claim 25 (depends on 23)

The method of claim 23, wherein the measured BAFF-R nucleic acid is BAFF-R DNA.

### Claim 26 (depends on 1, 23)

The method of claim 23, wherein the BAFF-R nucleic acid is measured using the nucleic acid of claim 1.

### Claim 27 (depends on 1, 23)

The method of claim 23, wherein the BAFF-R nucleic acid is measured by using one or more nucleic acids which amplify the nucleic acid of claim 1.

### Claim 28

A method of diagnosing a B-cell mediated condition in a subject, the method comprising:
providing a nucleic acid sample from said subject;
identifying at least a portion of the nucleotide sequence of a BAFF-R nucleic acid in said subject nucleic acid sample; and
comparing the BAFF-R nucleotide sequence of said subject sample to a BAFF-R nucleotide sequence of a control sample, wherein an alteration in the BAFF-R nucleotide sequence in said sample relative to the BAFF-R nucleotide sequence in said control sample indicates the subject has a B-cell mediated condition.

### Claim 29 (depends on 1)

A method of treating or preventing or delaying an autoimmune or tumorigenic condition, the method comprising administering to a subject in which such treatment or prevention or delay is desired the nucleic acid of claim 1 in an amount sufficient to treat, prevent, or delay an autoimmune or tumorigenic condition in said subject.

### Claim 30 (depends on 12)

A method of treating or preventing or delaying an autoimmune or tumorigenic condition, the method comprising administering to a subject in which such treatment or prevention or delay is desired the polypeptide of claim 12 in an amount sufficient to treat, prevent, or delay an autoimmune or tumorigenic condition in said subject.

### Claim 31 (depends on 16)

A method of treating or preventing or delaying an autoimmune or a tumorigenic condition, the method comprising administering to a subject in which such treatment or prevention or delay is desired the antibody of claim 16 in an amount sufficient to treat, prevent or delay an autoimmune or a tumorigenic condition in said subject.

### Claim 32

A method for identifying a compound that binds BAFF-R protein comprising:
a) contacting BAFF-R protein with a compound; and
b) determining whether said compound binds BAFF-R protein.

### Claim 33 (depends on 32)

A method of claim 32, wherein binding of said compound to BAFF-R protein is determined by a protein binding assay.

### Claim 34 (depends on 32)

A compound identified by the method of claim 32.

### Claim 35

A method for identifying a compound that binds a nucleic acid encoding BAFF-R protein comprising the steps of:
a) contacting said nucleic acid encoding BAFF-R protein with a compound; and
b) determining whether said compound binds said nucleic acid molecule.

### Claim 36 (depends on 35)

A compound identified by the method of claim 35.

### Claim 37

A method for identifying a compound that modulates the activity of BAFF-R protein comprising the steps of:
a) contacting BAFF-R protein with a compound; of
b) determining whether BAFF-R protein activity has been modulated.

### Claim 38 (depends on 37)

A compound identified by the method of claim 37.

### Claim 39

A method of decreasing aggregation of a recombinantly expressed protein comprising
a) identifying regions of conserved amino acids between homologs of a target protein that aggregates as a recombinantly expressed protein;
b) substituting at least one non-conserved amino acid in said target protein to form a mutated target protein;
wherein said mutated target protein displays reduced aggregation when recombinantly expressed.

### Claim 40 (depends on 39)

The method of claim 39 wherein said non-conserved amino acid is a nonpolar amino acid.

### Claim 41 (depends on 39)

The method of claim 39 wherein said nonpolar amino acid is changed to an uncharged polar amino acid.

### Claim 42 (depends on 39)

The method of claim 39 wherein said nonpolar amino acid is changed to an amino acid selected from the group consisting of proline, serine or alanine.

### Claim 43 (depends on 39)

The method of claim 39 wherein said nonpolar amino acid is changed to proline.

### Claim 44

An isolated nucleic acid molecule encoding at least a portion of a BAFF-R protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:13; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; and SEQ ED NO:32.

### Claim 45 (depends on 44)

The isolated nucleic acid molecule of claim 44 wherein said nucleic acid encodes said BAFF-R protein as a portion of a chimeric protein.

### Claim 46 (depends on 45)

The isolated nucleic acid of claim 45 wherein said chimeric protein comprises an immunoglobulin constant region.

### Claim 47

An isolated nucleic acid molecule encoding a BAFF-R protein comprising an amino acid sequence of SEQ ID NO:14.

### Claim 48 (depends on 47)

The isolated nucleic acid molecule of claim 47 wherein said nucleic acid encodes said BAFF-R protein as a portion of a chimeric protein.

### Claim 49 (depends on 48)

The isolated nucleic acid of claim 48 wherein said chimeric protein comprises an immunoglobulin constant region.

### Claim 50

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:13; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; and SEQ ID NO:32.

### Claim 51 (depends on 50)

The isolated polypeptide of claim 50 wherein said polypeptide is a chimeric protein.

### Claim 52 (depends on 51)

The isolated polypeptide of claim 51 wherein said chimeric protein comprises an immunoglobulin constant region.

### Claim 53

An isolated murine BAFF-R polypeptide comprising an amino acid sequence of SEQ ID NO:14.

### Claim 54 (depends on 53)

The isolated polypeptide of claim 53 wherein said polypeptide is a chimeric protein.

### Claim 55 (depends on 54)

The isolated polypeptide of claim 54 wherein said chimeric protein comprises an immunoglobulin constant region.
